Trulicity, on the other hand, is approved for the treatment of Type 2 diabetes
Mounjaro and Zepbound have not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and are therefore not recommended in these patients. Lilly additionally warned against the use of these products for individuals under the age of 18 years, citing that while clinical trials are ongoing, the safety and efficacy of tirzepatide have not been established in younger patients
The Precision Peptide Genetic Test (available for $298) can identify genetic predispositions in your GIPR, FTO, and MC4R pathwaysinforming whether you are a strong responder to GLP-1 therapy or may benefit from dual-compound approaches
Additionally, rapid weight loss can sometimes affect skin appearance, leading to sagging or wrinkling, a phenomenon often called "Ozempic face." If youre considering GLP-1 medications, its crucial to talk openly with your healthcare provider